Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.

Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, Dobrovic A, Birrer MJ, Webb PM, Stewart C, Friedlander M, Fox S, Bowtell D, Mitchell G.

J Clin Oncol. 2012 Jul 20;30(21):2654-63. doi: 10.1200/JCO.2011.39.8545. Epub 2012 Jun 18. Erratum in: J Clin Oncol. 2012 Nov 20;30(33):4180.

2.

Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.

Birkbak NJ, Wang ZC, Kim JY, Eklund AC, Li Q, Tian R, Bowman-Colin C, Li Y, Greene-Colozzi A, Iglehart JD, Tung N, Ryan PD, Garber JE, Silver DP, Szallasi Z, Richardson AL.

Cancer Discov. 2012 Apr;2(4):366-375. doi: 10.1158/2159-8290.CD-11-0206. Epub 2012 Mar 22. Erratum in: Cancer Discov. 2013 Aug;3(8):952.

3.

The DNA damage response and cancer therapy.

Lord CJ, Ashworth A.

Nature. 2012 Jan 18;481(7381):287-94. doi: 10.1038/nature10760. Review.

PMID:
22258607
4.

Chromosomal instability substantiates poor prognosis in patients with diffuse large B-cell lymphoma.

Bakhoum SF, Danilova OV, Kaur P, Levy NB, Compton DA.

Clin Cancer Res. 2011 Dec 15;17(24):7704-11. doi: 10.1158/1078-0432.CCR-11-2049.

5.

Identification of tumor suppressors and oncogenes from genomic and epigenetic features in ovarian cancer.

Wrzeszczynski KO, Varadan V, Byrnes J, Lum E, Kamalakaran S, Levine DA, Dimitrova N, Zhang MQ, Lucito R.

PLoS One. 2011;6(12):e28503. doi: 10.1371/journal.pone.0028503. Epub 2011 Dec 8.

6.

Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours.

Birch AH, Arcand SL, Oros KK, Rahimi K, Watters AK, Provencher D, Greenwood CM, Mes-Masson AM, Tonin PN.

PLoS One. 2011;6(12):e28250. doi: 10.1371/journal.pone.0028250. Epub 2011 Dec 6.

7.

Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.

Hyman DM, Zhou Q, Iasonos A, Grisham RN, Arnold AG, Phillips MF, Bhatia J, Levine DA, Aghajanian C, Offit K, Barakat RR, Spriggs DR, Kauff ND.

Cancer. 2012 Aug 1;118(15):3703-9. doi: 10.1002/cncr.26655. Epub 2011 Dec 2.

8.

Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.

Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK, Zhang W.

JAMA. 2011 Oct 12;306(14):1557-65. doi: 10.1001/jama.2011.1456. Erratum in: JAMA. 2012 Jan 25;307(4):363.

9.

Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers.

Vollebergh MA, Jonkers J, Linn SC.

Cell Mol Life Sci. 2012 Jan;69(2):223-45. doi: 10.1007/s00018-011-0809-0. Epub 2011 Sep 16. Review.

PMID:
21922196
10.

Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancer.

Roylance R, Endesfelder D, Gorman P, Burrell RA, Sander J, Tomlinson I, Hanby AM, Speirs V, Richardson AL, Birkbak NJ, Eklund AC, Downward J, Kschischo M, Szallasi Z, Swanton C.

Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2183-94. doi: 10.1158/1055-9965.EPI-11-0343. Epub 2011 Jul 22.

11.

Integrated genomic analyses of ovarian carcinoma.

Cancer Genome Atlas Research Network.

Nature. 2011 Jun 29;474(7353):609-15. doi: 10.1038/nature10166. Erratum in: Nature. 2012 Oct 11;490(7419):298.

12.

Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers.

Helland Å, Anglesio MS, George J, Cowin PA, Johnstone CN, House CM, Sheppard KE, Etemadmoghadam D, Melnyk N, Rustgi AK, Phillips WA, Johnsen H, Holm R, Kristensen GB, Birrer MJ; Australian Ovarian Cancer Study Group, Pearson RB, Børresen-Dale AL, Huntsman DG, deFazio A, Creighton CJ, Smyth GK, Bowtell DD.

PLoS One. 2011 Apr 13;6(4):e18064. doi: 10.1371/journal.pone.0018064.

13.

Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas.

Tan DS, Iravani M, McCluggage WG, Lambros MB, Milanezi F, Mackay A, Gourley C, Geyer FC, Vatcheva R, Millar J, Thomas K, Natrajan R, Savage K, Fenwick K, Williams A, Jameson C, El-Bahrawy M, Gore ME, Gabra H, Kaye SB, Ashworth A, Reis-Filho JS.

Clin Cancer Res. 2011 Mar 15;17(6):1521-34. doi: 10.1158/1078-0432.CCR-10-1688.

14.

IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer.

Anglesio MS, George J, Kulbe H, Friedlander M, Rischin D, Lemech C, Power J, Coward J, Cowin PA, House CM, Chakravarty P, Gorringe KL, Campbell IG; Australian Ovarian Cancer Study Group, Okamoto A, Birrer MJ, Huntsman DG, de Fazio A, Kalloger SE, Balkwill F, Gilks CB, Bowtell DD.

Clin Cancer Res. 2011 Apr 15;17(8):2538-48. doi: 10.1158/1078-0432.CCR-10-3314. Epub 2011 Feb 22.

15.

Paradoxical relationship between chromosomal instability and survival outcome in cancer.

Birkbak NJ, Eklund AC, Li Q, McClelland SE, Endesfelder D, Tan P, Tan IB, Richardson AL, Szallasi Z, Swanton C.

Cancer Res. 2011 May 15;71(10):3447-52. doi: 10.1158/0008-5472.CAN-10-3667. Epub 2011 Jan 26.

16.

Copy number analysis identifies novel interactions between genomic loci in ovarian cancer.

Gorringe KL, George J, Anglesio MS, Ramakrishna M, Etemadmoghadam D, Cowin P, Sridhar A, Williams LH, Boyle SE, Yanaihara N, Okamoto A, Urashima M, Smyth GK, Campbell IG, Bowtell DD; Australian Ovarian Cancer Study.

PLoS One. 2010 Sep 10;5(9). pii: e11408. doi: 10.1371/journal.pone.0011408.

17.

Genomic architecture characterizes tumor progression paths and fate in breast cancer patients.

Russnes HG, Vollan HKM, Lingjærde OC, Krasnitz A, Lundin P, Naume B, Sørlie T, Borgen E, Rye IH, Langerød A, Chin SF, Teschendorff AE, Stephens PJ, Månér S, Schlichting E, Baumbusch LO, Kåresen R, Stratton MP, Wigler M, Caldas C, Zetterberg A, Hicks J, Børresen-Dale AL.

Sci Transl Med. 2010 Jun 30;2(38):38ra47. doi: 10.1126/scitranslmed.3000611.

18.

Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones.

Eide MB, Liestøl K, Lingjaerde OC, Hystad ME, Kresse SH, Meza-Zepeda L, Myklebost O, Trøen G, Aamot HV, Holte H, Smeland EB, Delabie J.

Blood. 2010 Sep 2;116(9):1489-97. doi: 10.1182/blood-2010-03-272278. Epub 2010 May 26.

19.

Mechanisms of chromosomal instability.

Thompson SL, Bakhoum SF, Compton DA.

Curr Biol. 2010 Mar 23;20(6):R285-95. doi: 10.1016/j.cub.2010.01.034. Review.

20.

Genomic instability and the selection of treatments for cancer.

Martin SA, Hewish M, Lord CJ, Ashworth A.

J Pathol. 2010 Jan;220(2):281-9. doi: 10.1002/path.2631. Review.

PMID:
19890832

Supplemental Content

Support Center